Literature DB >> 8192456

Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses.

J Brajtburg1, S Elberg, G S Kobayashi, J Bolard.   

Abstract

The cellular activities of amphotericin B (AmB) used as Fungizone were compared with those of AmB complexed to either egg lecithin and glycocholate (Egam) or egg lecithin and deoxycholate (Edam). Under conditions in which leakage of K+ from erythrocytes and cultured L cells treated with Fungizone was almost complete, Egam and Edam containing concentrations of AmB severalfold greater than the concentration of AmB in Fungizone had no effect but retained the ability to decrease the level of retention of K+ in fungal cells. Analysis by absorption and circular dichroism spectroscopy demonstrated that when these formulations containing AmB at concentrations of less than 10(-5) M were added to buffer, the AmB dissociated slowly as monomers from Egam or Edam and dissociated rapidly as a mixture of monomers and self-associated species from Fungizone. We propose that in Egam and Edam, the absence of free AmB in the self-associated form reduces the toxicity of AmB to mammalian cells, whereas the presence of monomeric AmB results in the retention of the antifungal activities of these complexes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8192456      PMCID: PMC284444          DOI: 10.1128/AAC.38.2.300

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Liposomes as carriers of antifungal drugs.

Authors:  G Lopez-Berestein
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

2.  Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B.

Authors:  J Brajtburg; S Elberg; D R Schwartz; A Vertut-Croquin; D Schlessinger; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

3.  Interaction of plasma proteins and lipoproteins with amphotericin B.

Authors:  J Brajtburg; S Elberg; J Bolard; G S Kobayashi; R A Levy; R E Ostlund; D Schlessinger; G Medoff
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

4.  Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.

Authors:  J Brajtburg; S Elberg; S J Travis; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

5.  Stimulatory, permeabilizing, and toxic effects of amphotericin B on L cells.

Authors:  J Brajtburg; S Elberg; J Medoff; G S Kobayashi; D Schlessinger; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

6.  Circular dichroism for the determination of amphotericin B binding to liposomes.

Authors:  S Jullien; A Vertut-Croquin; J Brajtburg; J Bolard
Journal:  Anal Biochem       Date:  1988-07       Impact factor: 3.365

7.  The effects of amphotericin B on lipid metabolism in cultured human skin fibroblasts.

Authors:  R A Levy; R E Ostlund; J Brajtburg
Journal:  In Vitro Cell Dev Biol       Date:  1985-01

8.  Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B: lipid state and cholesterol content dependence.

Authors:  J Bolard; M Seigneuret; G Boudet
Journal:  Biochim Biophys Acta       Date:  1980-06-20

9.  Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits.

Authors:  M H Koldin; G S Kobayashi; J Brajtburg; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

10.  Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids.

Authors:  S Jullien; A Contrepois; J E Sligh; Y Domart; P Yeni; J Brajtburg; G Medoff; J Bolard
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

View more
  8 in total

1.  Amphotericin B augments interleukin-6 production by human gingival fibroblasts in vitro.

Authors:  C A Lapp
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-09       Impact factor: 2.416

2.  Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index.

Authors:  F Gaboriau; M Chéron; C Petit; J Bolard
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 3.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

4.  Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis.

Authors:  R Santangelo; P Paderu; G Delmas; Z W Chen; R Mannino; L Zarif; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.

Authors:  J A Sánchez-Brunete; M A Dea; S Rama; F Bolás; J M Alunda; R Raposo; M T Méndez; S Torrado-Santiago; J J Torrado
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

6.  Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.

Authors:  J Brajtburg; S Elberg; S J Travis; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  Comparison of bile salt/phosphatidylcholine mixed micelles in solubilization to sterols and stability.

Authors:  Qin Guo; Jie Cai; Pengyu Li; Dongling Xu; Xiaomin Ni; Hui Wen; Dan Liu; Suizhen Lin; Haiyan Hu
Journal:  Drug Des Devel Ther       Date:  2016-11-17       Impact factor: 4.162

Review 8.  Optimizing efficacy of amphotericin B through nanomodification.

Authors:  Suresh P Vyas; Swati Gupta
Journal:  Int J Nanomedicine       Date:  2006
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.